Table 1.

Starting criteria for first and after second cycle of carboplatin, pemetrexed and pembrolizumab

	First cycle	After second cycle
Treatment	All	CBDCA, PEM	Pembrolizumab
ECOG PS	0–1	0–2	0–2
Neutrophils (/mm3)	≥1500	≥1500	N/A
Haemoglobin (g/L)	0.8	0.8	N/A
Platelet (/L)	≥100×109	≥100 ×109	N/A
AST, ALT	≤100 (≤150 when with liver metastasis)	≤100 (≤150 when with liver metastasis)	N/A
Total bilirubin (mg/dL)	≤2	≤2	N/A
Creatinine clearance	≥45 mL/min	≥45 mL/min	N/A
Constipation, appetite loss, nausea, vomit, oral mucositis, fatigue, phlebitis	N/A	≥Grade 2	N/A
Other medication related non-haematological adverse events except for hyponatraemia, alopecia, weight loss	N/A	≥Grade 1	N/A
Pneumonitis	N/A	Grade 0	See below
Immune-related adverse events (eg, pneumonitis, hepatitis, colitis, endocrine disorder*, eye disorder, myocarditis, neuropathy, etc.)	N/A	N/A	≤Grade 1
Amylase increase, hyperglycaemic, skin disorder	N/A	N/A	≤Grade 2
Immune-related cerebromeningitis	N/A	N/A	Grade 0
Non-haematological adverse events	N/A	N/A	≤Grade 2

*Hypothyroidism, hypopituitarism (ACTH secretion deficiency) and type 1 diabetes that are stable with hormone replacement therapy can be administered.

ACTH, adrenocorticotropic hormone; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; CBDCA, carboplatin; ECOG, Eastern Cooperative Oncology Group; N/A, not applicable; PEM, pemetrexed; PS, performance status.